C-peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy

Diabetes Care

Volumn 30, Issue 1, 2007, Pages 71-76

  Ekberg, Karin ^a,e   Brismar, Tom ^a   Johansson, Bo Lennart ^a   Lindstr̈om, Per ^a   Juntti Berggren, Lisa ^a   Norrby, Anders ^b   Berne, Christian ^c   Arnqvist, Hans J ^d   Bolinder, Jan ^a   Wahren, John ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Capio AB   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e Creative Peptides   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; INSULIN; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; HORMONE SUBSTITUTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NERVE FUNCTION; NEUROLOGIC EXAMINATION; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SENSORY NERVE; SENSORY NERVE CONDUCTION;

ADULT; AGE OF ONSET; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; HUMANS; MIDDLE AGED; NEURAL CONDUCTION; NEUROLOGIC EXAMINATION; PATIENT SELECTION; SURAL NERVE; SWEDEN;

EID: 33846075220     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-1274     Document Type: Article

References (33)

1. Sima AA, Nathaniel V, Bril V, McEwen T, Green D: Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy. J Clin Invest 81:349 -364, 1988
2. Sima AA: Diabetic neuropathy in type 1 and 2 diabetes and the effect of C-peptide. J Neurol Sci 220:133-136, 2004
3. Dyck P, Davies J, Wilson D, Service F, Melton LI, O'Brien P: Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study Cohort. Diabetes Care 22:1479-1486, 1999
4. Sugimoto K, Murakawa Y, Sima A: Diabetic neuropathy - a continuing enigma. Diabetes Metab Res Rev 16:408-433, 2000
5. +-ATPase activity in the pathogenesis of human diabetic neuropathy. J Neurol Sci 120:159-167, 1993
6. + pump concentration in skeletal muscle, heart ventricular muscle, and peripheral nerves of rat. Diabetes 36:842-848, 1987
7. Cotter M, Ekberg K, Wahren J, Cameron N: Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition. Diabetes 52:1812-1817, 2003
8. Malik R, Tesfaye S, Newrick D, Walker D, Rajbhandari S, Siddique I, Sharma A, Boulton A, King R, Thomas P, Ward J: Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetelogia 48:578 -585, 2005
9. Sima AA, Lattimer SA, Yagihashi S, Greene DA: Axo-glial dysjunction: a novel structural lesion that accounts for poorly reversible slowing of nerve conduction in the spontaneous diabetic BB rat. J Clin Invest 77:474-484, 1986
10. +-channel displacement is associated with nerve conduction slowing in the chronically diabetic BB/W rat: prevention by aldose reductase inhibitor. J Diabetes Complications 10:192-200, 1996
11. Kamiya H, Murakawa Y, Zhang W, Sima AA: Unmyelinated fiber sensory neuropathy differs in type 1 and type 2 diabetes. Diabetes Metab Res Rev 21:448-458, 2005
12. Sima A, Zhang W, Li Z, Murakawa Y, Pierson C: Molecular alterations underlie nodal and paranodal degeneration in type 1 diabetic neuropathy and are prevented by C-peptide. Diabetes 53:1556-1563, 2004
13. Sima AA, Zhang W, Sugimoto K, Henry D, Li Z, Wahren J, Grunberger G: C-peptide prevents and improves chronic type 1 diabetic polyneuropathy in the BB/Wor rat. Diabetologia 44:889-897, 2001
14. Ido Y, Vindigni A, Chang K, Stramm L, Chance R, Heath W, DiMarchi R, DiCera E, Williamson J: Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science 277:563-566, 1997
15. Wallerath T, Kunt T, Forst T, Closs E, Lehmann R, Flohr T, Gabriel M, Schäfer D, Göpfert A, Pfützner A, Beyer J, Förstermann U: Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide. Nitric Oxide 9:95-102, 2003
16. Kitamura T, Kimura K, Makondo K, Furuya T, Suzuki M, Yoshida T, Saito M: Proinsulin C-peptide increases nitric oxide production by enhancing mitogen-activated protein-kinase-dependent transcription of endothelial nitric oxide synthase in aortic endothelial cells of Wistar rats. Diabetologia 46:1698-1705, 2003
17. Stevens M, Zhang W, Li F, Sima A: C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor rats. Am J Physiol 287:E497-E505, 2004
18. Sima AA, Zhang W, Grunberger G: Type 1 diabetic neuropathy and C-peptide. Exp Diabesity Res 5:65-77, 2004
19. Ekberg K, Brismar T, Johansson B-L, Jonsson B, Lindström P, Wahren J: Amelioration of sensory nerve dysfunction by C-peptide in patients with type 1 diabetes. Diabetes 52:536 -541, 2003
20. Johansson B-L, Borg K, Fernqvist-Forbes E, Odergren T, Remahl S, Wahren J: C-peptide improves autonomic nerve function IDDM patients. Diabetologia 39:687-695, 1996
21. Report and recommendations of the San Antonio Conference on diabetic neuropathy. Ann Neurol 24:99 -104, 1988
22. Hansson P, Lindblom U, Lindström P: Graded assessment and classification of impaired temperature sensibility in patients with diabetic polyneuropathy. J Neurol Neurosurg Psychiatry 54:527-530, 1991
23. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 38:869-880, 1995
24. Vinik A, Bril V, Litchy W, Price K, Bastyr ER, the MBBQ Study Group: Sural sensory action potential identifies diabetic peripheral neuropathy responders to therapy. Muscle Nerve 32:619-625, 2005
25. Boulton A, Vinik A, Arezzo J, Bril V, Feldman E, Freeman R, Malik RA, Maser R, Sosenko J, Ziegler D: Diabetic neuropathies. Diabetes Care 24:956 -960, 2005
26. Rigler R, Pramanik A, Jonasson P, Kratz G, Jansson O, Nygren P-Å, Ståhl S, Ekberg K, Johansson B-L, Uhlén S, Uhlén M, Jörnvall H, Wahren J: Specific binding of proinsulin C-peptide to human cell membranes. Proc Natl Acad Sci U S A 96:13318-13323, 1999
27. Zhong Z, Davidescu A, Ehrén I, Ekberg K, Jörnvall H, Wahren J, Chibalin A: C-peptide stimulates ERK1/2 and JNK MAP-kinases via activation of PKC in human renal tubular cells. Diabetologia 48:187-197, 2005
28. Zhang W, Yorek M, Pierson C, Murakawa Y, Breidenbach A, Sima A: Human C-peptide dose dependently prevents early neuropathy in the BB/Wor rat. Int J Exp Diabetes Res 2:187-193, 2001
29. Ekberg K, Johansson B-L, Wahren J: Stimulation of blood flow by C-peptide in patients with type 1 diabetes (Abstract). Diabetologia 44 (Suppl. 1):A323, 2001
30. Bril V, Buchanan R, the AS-3201 Study Group: Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care 27:2369-2375, 2004
31. Bril V, Buchanan R, the Ranirestat Study Group: Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 29:68-72, 2005
32. Laudadio C, Sima AA: Progression rates of diabetic neuropathy in placebo patients in an 18-month clinical trial: Ponalrestat Study Group. J Diabetes Complications 12:121-127, 1998
33. Thomas P: Diabetic neuropathy: mechanisms and future treatment options. J Neurol Neurosurg Psychiatry 67:277-279, 1999